Actively Recruiting
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Led by Case Western Reserve University · Updated on 2026-04-03
208
Participants Needed
1
Research Sites
328 weeks
Total Duration
On this page
Sponsors
C
Case Western Reserve University
Lead Sponsor
U
University Hospitals Cleveland Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Hypertension (HTN) has a greater impact on African Americans (AA) than any other U.S. racial group. Uncontrolled blood pressure (BP) contributes to higher rates of disability, death, and health resource use among AA. HTN is the single most influential risk factor for cardiovascular disease (CVD), as well as a risk factor for the incidence of stroke, diabetes, chronic kidney disease, and dementia. Importantly, older adults account for 15% of the U.S. population, and two-thirds of older adults over age 60 have HTN, with higher rates observed in AA older adults. Strategies to support self-managing HTN and BP control are crucial as the older population is projected to age considerably and become more racially and ethnically diverse. Research has documented the negative effects on health and health outcomes of poorly controlled BP and is one of the most important modifiable CVD risk factors. Lower BP targets will require aggressive management and an increase in antihypertensive medications. Therefore, to achieve lower targets in this population, greater efforts, including patient-centered methods will be needed to support self-managing HTN, especially in terms of medication adherence. As we shifted into the digital age, the use of mHealth technologies (smart phones, applications, SMS or text messaging) has been a powerful approach and mechanism for the treatment and management of chronic diseases. However, behavioral interventions that incorporate technology do not reach minorities or disadvantaged AA older adults with HTN. OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP) will leverage existing knowledge of effective technology-based components for HTN self-management to support and improve BP control using unique aspects of mHealth platforms in AA older adults. Findings from this study, if confirmed, will improve BP control and support self-managing HTN, as well as has the potential to close the health disparity gap between AA and non-AA older adults with HTN.
CONDITIONS
Official Title
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Self-identify as African American
- 50 years of age or older
- Diagnosed with hypertension, with a systolic blood pressure 63 130 mmHg but less than 170 mmHg
- Prescribed at least two hypertensive medications, one of which is a diuretic/thiazide or calcium channel blocker
- Own a smartphone with a data plan and the capability to download the Medisafe app or view videos
- Able to read and understand English
You will not qualify if you...
- Unable to give informed consent or judged to have impaired cognitive ability or severe memory problems
- Currently using a medication management application (app)
- Experienced a major cardiovascular event or procedure such as myocardial infarction, stroke, or heart surgery within the past year
- Diagnosed with chronic kidney disease (eGFR < 60 ml/min/1.73m2) or receiving dialysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Case Western Reserve University
Cleveland, Ohio, United States, 44143
Actively Recruiting
Research Team
C
Carolyn Still, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here